Safety, Pharmacovigilance and Benefit–Risk
- Safety Monitoring & Risk Mitigation in Clinical Development
- Signal detection & aggregate reporting; RMPs/REMS
- Risk–benefit frameworks and patient-centric safety endpoints
- Post-marketing safety, pregnancy registries, and special populations
- Device/combination product vigilance
Drug safety doesn’t end with approval—it evolves continuously. Safety, Pharmacovigilance & Benefit–Risk explores the systems, science, and governance that protect patients throughout a medicine’s lifecycle. This session highlights how proactive surveillance, data integration, and regulatory alignment can detect signals earlier, respond faster, and communicate risks transparently. Attendees will gain a deep understanding of global pharmacovigilance frameworks—FDA FAERS, EMA EudraVigilance, MHRA Yellow Card, and WHO VigiBase—and how these databases inform modern signal detection strategies.
Key areas include aggregate reporting, RMPs/REMS planning, and benefit–risk modeling using Bayesian and causal inference approaches. The track emphasizes how AI and natural language processing are transforming case intake, coding, and literature monitoring. Participants will explore signal validation workflows, quantitative disproportionality analysis, and the creation of integrated safety datasets across clinical, post-marketing, and real-world evidence sources. The goal is to move from reactive to predictive safety management.
Case studies demonstrate how companies have applied integrated pharmacovigilance systems to manage emerging risks, such as immunogenicity, class-wide toxicities, or device malfunctions. The session also delves into risk communication—developing plain-language summaries, field safety notices, and regulatory submissions that balance transparency with accuracy. For professionals attending a Pharmaceutical Conference, this session provides a comprehensive review of evolving legislation, from EU GVP Module revisions to FDA’s Sentinel Initiative. The importance of quantitative benefit–risk assessment frameworks is also explored, showing how structured decision-making supports both regulators and sponsors.
With pharmacovigilance becoming increasingly data-driven, this session helps organizations design end-to-end safety architectures—spanning signal management, aggregate reporting, and periodic safety updates—supported by validated technology platforms and global compliance systems.
Ready to Share Your Research?
Submit Your Abstract Here →Present your research under Safety, Pharmacovigilance and Benefit–Risk
Key Safety Domains and Insights
Signal Detection & Validation
- Data mining, disproportionality metrics, and NLP-assisted case review.
- Workflow design ensuring traceability and decision documentation.
Aggregate Reporting & Risk Plans
- RMP/REMS lifecycle management with adaptive control strategies.
- Periodic reporting harmonized with global regulatory timelines.
Post-Marketing Surveillance
- Active and passive surveillance integrating real-world evidence.
- Automated case intake pipelines improving response speed.
Quantitative Benefit–Risk
- Structured frameworks (MCDA, BRAT) for balanced evaluations.
- Transparency tools improving communication to stakeholders.
AI in Pharmacovigilance
- Machine learning for triage, causality, and literature monitoring.
- Automation that scales case processing and regulatory submissions.
Safety Governance & Culture
- Embedding accountability, quality, and cross-functional safety review.
- Training models fostering proactive safety mindset.
Protecting Patients and Building Trust
Predictive Safety Science
Transforms pharmacovigilance into a forward-looking discipline.
Real-Time Intelligence
Harnesses global databases for immediate safety awareness.
Compliance Mastery
Aligns systems with GVP, FDA, and ICH requirements.
Risk Communication
Delivers transparent messages that enhance confidence.
Data-Driven Decision-Making
Applies quantitative benefit–risk models across portfolios.
Technology Enablement
Implements AI, automation, and dashboards for efficiency.
Continuous Improvement
Uses metrics and audits to enhance PV performance.
Patient-Centric Vigilance
Places human safety at the center of every lifecycle stage.
Related Sessions You May Like
Join the Global Pharmaceutical Sciences Community
Connect with top researchers, industry experts, and innovators worldwide. Share your work and explore the latest advancements in drug discovery, translational research, and next-generation therapeutics.
